Yeo Melissa R, Voutsadakis Ioannis A
Northern Ontario School of Medicine, Sudbury, ON P3E 2C6, Canada.
Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, ON P6B 0A8, Canada.
Cancers (Basel). 2025 Jan 14;17(2):247. doi: 10.3390/cancers17020247.
Colorectal cancer primarily affects older adults and poses treatment challenges due to age-related comorbidities and frailty, which hinder surgical and chemotherapy options for many elderly patients. This study aims to analyze treatment and disease patterns in elderly colorectal cancer patients, aged over 80 years old, to inform personalized therapies that accommodate their unique clinical needs and improve their outcomes.
The medical records of all patients aged 80 years old and above, and those aged 65 to 75 years old, who were diagnosed with colorectal cancer at a cancer center in Canada over a seven year period, were retrospectively reviewed.
No significant differences in the initial presentation, location, grade or stage at colorectal cancer diagnosis were observed between age groups. Patients aged 80 years old and above were less likely to receive neoadjuvant and adjuvant chemotherapy treatments for stage II disease (19.2% versus. 58.6%, = 0.002; 7.9% versus. 40.0%, = 0.002). There were also differences in the intensity of chemotherapy received and the frequency of dose reductions (76.0% vs. 10.0%, = 0.0001), neoadjuvant and adjuvant radiation therapy (34.6% vs. 65.5%, = 0.02) and surgical management (83.7% vs. 95.3%, = 0.006). Despite these differences in treatments, recurrence rates were not statistically significant between the two groups. However, overall survival was reduced in the older age group.
Treatment plans for patients aged 80 years old and above should be tailored to the patient's colorectal cancer presentation, comorbidity status and life expectancy, weighing the impact of cancer treatments on the patient's short- and long-term outcomes.
结直肠癌主要影响老年人,由于与年龄相关的合并症和身体虚弱,给治疗带来挑战,这限制了许多老年患者的手术和化疗选择。本研究旨在分析80岁以上老年结直肠癌患者的治疗和疾病模式,以提供个性化治疗方案,满足其独特的临床需求并改善治疗效果。
回顾性分析了加拿大某癌症中心7年间诊断为结直肠癌的所有80岁及以上患者以及65至75岁患者的病历。
各年龄组在结直肠癌诊断时的初始表现、部位、分级或分期方面未观察到显著差异。80岁及以上患者患II期疾病接受新辅助化疗和辅助化疗的可能性较小(分别为19.2%对58.6%,P = 0.002;7.9%对40.0%,P = 0.002)。在接受化疗的强度、剂量减少频率(76.0%对10.0%,P = 0.0001)、新辅助和辅助放疗(34.6%对65.5%,P = 0.02)以及手术治疗方面(83.7%对95.3%,P = 0.006)也存在差异。尽管治疗存在这些差异,但两组的复发率无统计学显著差异。然而,老年组的总生存期缩短。
80岁及以上患者的治疗计划应根据患者的结直肠癌表现、合并症状况和预期寿命进行调整,权衡癌症治疗对患者短期和长期结局的影响。